Recent Acquisition Evergreen Theragnostics was acquired by Lantheus Holdings for $250 million, indicating strong industry validation and potential collaboration opportunities with a major player in radiopharmaceuticals, opening doors for strategic partnerships or licensing deals.

Growing Funding The company secured $26 million in recent funding and completed a $15 million Series B round, demonstrating robust investor confidence and providing additional capital to expand manufacturing capacity and R&D efforts.

Product Development & Partnerships With collaborations with Jubilant Radiopharma and RLS (USA) Inc., Evergreen Theragnostics is actively involved in bringing radiopharmaceutical products like OCTEVY to market, presenting opportunities to supply additional radiochemicals or related medical devices.

Market Focus Positioned as a clinical-stage CDMO specializing in theragnostic radiopharmaceuticals, Evergreen offers potential sales avenues for companies seeking manufacturing partnerships for cancer-targeted radiopharmaceuticals and related therapy products.

Technology & Innovation The company’s launch of a new discovery unit and strategic team hires, including a Chief Scientific Officer, indicate ongoing innovation and pipeline development, which can be leveraged to identify opportunities for collaborative R&D, technology licensing, and supply chain solutions.